The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.

The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news.

The following are key catalysts in the unfolding week that a biotech investor should stay tuned to.

Conferences

Barclays Global Healthcare Conference: March 10-12 in Miami, Florida.
American Academy of Allergy Asthma and Immunology, or AAAAI, Annual Meeting: March 13-16 in Philadelphia, Pennsylvania.

PDUFA Dates

The FDA is set to rule on Bristol-Myers Squibb Co's (NYSE:BMY) sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG (OTC:BAYRY) and Onyx Pharma's Nexavar. The PDUFA date has been set for Tuesday.

Clinical Readouts

Blueprint Medicines Corp (NASDAQ:BPMC) is scheduled to present at the AAAAI annual meeting with Phase 2 data for Avapritinib, which is being evaluated for treating indolent and smoldering systemic mastocytosis.

Earnings

Monday

Matinas BioPharma Holdings Inc (NYSE:MTNB) (before the market open)
Minerva Neurosciences Inc (NASDAQ:NERV) (before the market open)
BioXcel Therapeutics Inc (NASDAQ:BTAI) (before the market open)
Assertio Therapeutics Inc (NASDAQ:ASRT) (after the close)
SI-Bone Inc (NASDAQ:SIBN) (after the close)
Xenon Pharmaceuticals Inc (NASDAQ:XENE) (after the close)
Organogenesis Holdings Inc (NASDAQ:ORGO) (after the close)
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) (after the close)

Tuesday

Precision BioSciences Inc (NASDAQ:DTIL) (time not provided)
Akebia Therapeutics Inc (NASDAQ:AKBA) (before the market open)
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) (before the market open)
InspireMD Inc (NYSE:NSPR) (before the market open)
ChemoCentryx Inc (NASDAQ:CCXI) (after the close)
CV Sciences Inc (OTC:CVSI) (after the close)
Fulgent Genetics Inc (NASDAQ:FLGT) (after the close)
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) (after the close)
RA Medical Systems Inc (NYSE:RMED) (after the close)
Protagonist Therapeutics Inc (NASDAQ:PTGX) (after the close)

Wednesday

Xeris Pharmaceuticals Inc (NASDAQ:XERS) (before the market open)
Liquidia Technologies Inc (NASDAQ:LQDA) (before the market open)
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) (before the market open)
INmune Bio Inc (NASDAQ:INMB) (before the market open)
Clearside Biomedical Inc (NASDAQ:CLSD) (after the close)
Calithera Biosciences Inc (NASDAQ:CALA) (after the close)
Unity Biotechnology Inc (NASDAQ:UBX) (after the close)
Navidea Biopharmaceuticals Inc (NYSE:NAVB) (after the close)
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) (after the close)
BioLife Solutions Inc (NASDAQ:BLFS) (after the close)
Dynavax Technologies Corporation (NASDAQ:DVAX) (after the close)
Miragen Therapeutics Inc (NASDAQ:MGEN) (after the close)
Pfenex Inc (NYSE:PFNX) (after the close)
Thursday
Aquestive Therapeutics Inc (NASDAQ:AQST) (before the market open)
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) (before the market open)
Axsome Therapeutics Inc (NASDAQ:AXSM) (before the market open)
Aldeyra Therapeutics Inc (NASDAQ:ALDX) (before the market open)
Selecta Biosciences Inc (NASDAQ:SELB) (before the market open)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) (before the market open)
Provention Bio Inc (NASDAQ:PRVB) (before the market open)
Protalix Biotherapeutics Inc (NYSE:PLX) (before the market open)
Evofem Biosciences Inc (NASDAQ:EVFM) (before the market open)
China Biologic Products Holdings Inc (NASDAQ:CBPO) (before the market open)
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) (before the market open)
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) (before the market open)
X4 Pharmaceuticals Inc (NASDAQ:XFOR) (before the market open)
Polarityte Inc (NASDAQ:PTE) (before the market open)
Rubius Therapeutics Inc (NASDAQ:RUBY) (before the market open)
Agenus Inc (NASDAQ:AGEN) (before the market open)
ADMA Biologics Inc (NASDAQ:ADMA) (after the close)
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) (after the close)
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) (after the close)
Celcuity Inc (NASDAQ:CELC) (after the close)
Lineage Cell Therapeutics Inc (NYSE:LCTX) (after the close)
Chembio Diagnostics Inc (NASDAQ:CEMI) (after the close)
Harpoon Therapeutics Inc (NASDAQ:HARP) (after the close)
Flexion Therapeutics Inc (NASDAQ:FLXN) (after the close)
Neoleukin Therapeutics Inc (NASDAQ:NLTX) (after the close)
Rockwell Medical Inc (NASDAQ:RMTI) (after the close)
Inovio Pharmaceuticals Inc (NASDAQ:INO) (after the close)
Savara Inc (NASDAQ:SVRA) (after the close)
Ocular Therapeutix Inc (NASDAQ:OCUL) (after the close)
Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) (after the close)

Friday

PLx Pharma Inc (NASDAQ:PLXP) (before the market open)
Achieve Life Sciences Inc (NASDAQ:ACHV) (before the market open)

IPOs

Imara, a biopharma company that is developing therapies for rare hemoglobinopathies, has filed to offer 4.45 million shares in an IPO, to be priced between $16 and $18. The company seeks to list its shares on the Nasdaq under the ticker symbol "IMRA."